iOnctura to Present Research on Roginolisib and IOA-359 at ASH

Three abstracts accepted by ASH with two poster presentations

Geneva, Switzerland and Amsterdam, The Netherlands, 3 November 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, from 9-12 December 2023.

Read more…